BioLineRX
BLRX
13 hedge funds and large institutions have $45.2K invested in BioLineRX in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.65% less ownership
Funds ownership: 1.1% → 0.45% (-0.65%)
7% less funds holding
Funds holding: 14 → 13 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
67% less capital invested
Capital invested by funds: $136K → $45.2K (-$90.4K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$30.7K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$842 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.99K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$2.81K |
| 4 |
Citigroup
New York
|
-$870 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$28 |
BLRX Hedge Fund Activity: Q1 2026 in Review
13 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2026, worth a combined $45.2K — down 67% from $136K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BLRX and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $30.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $104K sold.
- 13 institutional investors held BioLineRX (BLRX) as of Q1 2026, down from 14 in Q4 2025.
- Funds reported $45.2K of BioLineRX stock for Q1 2026, down 67% quarter-over-quarter.
- 1 fund opened new BioLineRX positions in Q1 2026 and 2 closed out, a net change of -1 holder.
- The largest BioLineRX buyer in Q1 2026 was XTX Topco, an estimated $30.7K added.
- The largest BioLineRX seller in Q1 2026 was Citadel Advisors, an estimated $104K sold.
Based on aggregated 13F filings for Q1 2026.